Lung cancer patients get new hope from Drug-Radiation combo
NCT ID NCT02839265
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of FLT3 ligand immunotherapy (CDX-301) and stereotactic body radiotherapy (SBRT) in 33 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if this approach could slow cancer growth. Patients received daily injections of the immunotherapy for five days starting with the first radiation session. The study measured how many patients were alive without their cancer getting worse after four months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FLT3 ligand (CDX-301) and stereotactic body radiotherapy
- What this could lead to
- If it works, this combination could offer a new treatment option for advanced lung cancer patients who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The treatment also carries risks of serious side effects from both the drug and radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Custom-Made vaccine aims to stop lung cancer recurrence
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug